Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Gains from Investment Securities (2020 - 2025)

Tarsus Pharmaceuticals has reported Gains from Investment Securities over the past 5 years, most recently at $381000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $381000.0 for Q4 2025, down 61.82% from a year ago — trailing twelve months through Dec 2025 was $527000.0 (down 40.79% YoY), and the annual figure for FY2025 was $527000.0, up 37.24%.
  • Gains from Investment Securities for Q4 2025 was $381000.0 at Tarsus Pharmaceuticals, up from $373000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for TARS hit a ceiling of $5.5 million in Q1 2021 and a floor of -$5.6 million in Q2 2021.
  • Median Gains from Investment Securities over the past 4 years was $373000.0 (2025), compared with a mean of $83133.3.
  • Peak annual rise in Gains from Investment Securities hit 1152.63% in 2024, while the deepest fall reached 1078.43% in 2024.
  • Tarsus Pharmaceuticals' Gains from Investment Securities stood at -$2.0 million in 2021, then soared by 161.26% to $1.2 million in 2023, then dropped by 19.39% to $998000.0 in 2024, then crashed by 61.82% to $381000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $381000.0 (Q4 2025), $373000.0 (Q3 2025), and -$227000.0 (Q2 2025) per Business Quant data.